Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Aramark’s latest analyst update keeps the model fair value steady at US$46.63, while several firms are now talking about price targets clustering closer to US$50. Much of this shift in targets is being linked to commentary around organic growth, contract wins such as RWJ Barnabas Health, and expectations for earnings and cash flow through 2026. As you read on, you will see how these moving parts shape the current narrative and what to watch as it evolves.
Stay updated as the Fair Value for Aramark shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Aramark.
-
Truist lifted its Aramark price target to US$50 from US$46, pointing to organic growth that ran ahead of its expectations and highlighting the RWJ Barnabas Health contract that is scheduled to start ramping in June 2026.
-
BofA reinstated coverage with a US$50 price target, grouping Aramark within a broader set of Information and Business Services stocks where the firm is generally positive and using 2026 revenue, EPS and free cash flow growth assumptions for the group as a reference point.
-
UBS, Morgan Stanley, JPMorgan and Stifel each raised their Aramark price targets, which collectively adds to the sense that coverage is coalescing around higher valuation markers compared with prior reports from these firms.
-
The cluster of US$50 targets from Truist and BofA may limit perceived upside against some existing fair value estimates such as US$46.63. This can make entry points and execution on growth plans more important for investors to watch.
-
Several research notes reference expectations for 2026 earnings, cash flow and contract ramps, which means results over the next few years will likely be scrutinized closely against these assumptions.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 1 risk for Aramark. See which could impact your investment.
-
Aramark completed the repurchase of 4,773,392 shares, representing 1.8% of its shares, for a total of US$168.56m under the buyback announced on November 11, 2024. This included 792,445 shares, or 0.3%, bought for US$29.26m between October 4, 2025 and January 2, 2026.
-
The company issued fiscal 2026 guidance, with expected revenue in a range of US$19.55b to US$19.95b and year over year organic growth of 7% to 9%.
-
Aramark announced a 15 year partnership with the University at Albany to revamp campus dining from January 2026. The partnership features a new food hall, a Global Food Emporium concept, technology enabled ordering and checkout, a student operated Saxbys cafe, and expanded inclusive dining options.